From: Primary immunodeficiency
 | Gammagard S/D, (Baxter) | Gamunex/IGIVnex, Talecris (Biotherapeutics) | Gammagard Liquid, (Baxter) | Privigen CSL, (Behring Canada) | Vivaglobin CSL, (Behring Canada) |
---|---|---|---|---|---|
Formulation | Lyophilized | Liquid | Liquid | Liquid | Liquid |
Administration | IV | IV | IV | IV | SC |
Concentration | 5% or 10% upon reconstitution | 9%-11% | 9%-11% | 10% | 16% |
Shelf-life | Not specified | 36 months | 36 months | Not specified | 24 months |
Storage requirements | Up to 25°C Do not freeze | 2°C-8°C (36 mo), up to 25°C (6 mo) Do not freeze | 2°C-8°C (36 mo), up to 25°C (for a single period of up to 9 mo within the first 24 mo from date of manufacture) Do not freeze | Room temperature (up to 25°C) Do not freeze Keep in the original carton to protect it from light | 2-8°C (24 mo) Do not freeze Keep vials in storage box until use Do not administer if vial has been opened more than 4 h |
Infusion rate and dosage | For 5% solution: 4 mL/kg/h, maximum (3.3 mg/kg/min, maximum) For 10% solution: 8 mL/kg/h, maximum (calculated rate:13.3 mg/kg/min, maximum) | 0.14 mL/kg/min (14 mg/kg/min, maximum) | 8 mL/kg/h maximum (calculated rate: 13.3 mg/kg/min, maximum) | 0.08 mL/kg/ min, maximum (8 mg/kg/min) | 100-200 mg/kg weekly; maximum volume of 15 mL per injection site at a rate of 20 mL/h Previous IV Ig dose ×1.37, then divide into weekly dose based on previous IV Ig interval |